Monogram Orthopaedics (NASDAQ:MGRM) Coverage Initiated by Analysts at Roth Mkm

Equities researchers at Roth Mkm assumed coverage on shares of Monogram Orthopaedics (NASDAQ:MGRM) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $4.00 price target on the stock. Roth Mkm’s target price would suggest a potential upside of 77.78% from the stock’s current price.

Monogram Orthopaedics Trading Up 2.3 %

NASDAQ:MGRM opened at $2.25 on Monday. Monogram Orthopaedics has a 1-year low of $1.53 and a 1-year high of $4.90. The firm has a market capitalization of $77.20 million, a price-to-earnings ratio of -4.79 and a beta of 2.01. The business’s fifty day moving average price is $2.26 and its 200 day moving average price is $2.39.

Institutional Investors Weigh In On Monogram Orthopaedics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC purchased a new stake in shares of Monogram Orthopaedics during the third quarter worth $29,000. State Street Corp purchased a new position in Monogram Orthopaedics in the third quarter valued at about $62,000. Finally, Geode Capital Management LLC increased its position in Monogram Orthopaedics by 1,267.4% in the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock worth $557,000 after purchasing an additional 194,776 shares during the last quarter. Hedge funds and other institutional investors own 0.45% of the company’s stock.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.